Abstract:Mycoplasma pulmonis (M. pulmonis) is an emerging respiratory infection commonly linked to prostate cancer, and it is classified under the group of mycoplasmas. Improved management of mycoplasma infections is essential due to the frequent ineffectiveness of current antibiotic treatments in completely eliminating these pathogens from the host. The objective of this study is to design and construct effective and protective vaccines guided by structural proteomics and machine learning algorithms to provide protection against the M. pulmonis infection. Through a thorough examination of the entire proteome of M. pulmonis, four specific targets Membrane protein P80, Lipoprotein, Uncharacterized protein and GGDEF domain-containing protein have been identified as appropriate for designing a vaccine. The proteins underwent mapping of cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL) (IFN)-γ ±, and B-cell epitopes using artificial and recurrent neural networks. The design involved the creation of mRNA and peptide-based vaccine, which consisted of 8 CTL epitopes associated by GGS linkers, 7 HTL (IFN-positive) epitopes, and 8 B-cell epitopes joined by GPGPG linkers. The vaccine designed exhibit antigenic behavior, non-allergenic qualities, and exceptional physicochemical attributes. Structural modeling revealed that correct folding is crucial for optimal functioning. The coupling of the MEVC and Toll-like Receptors (TLR)1, TLR2, and TLR6 was examined through molecular docking experiments. This was followed by molecular simulation investigations, which included binding free energy estimations. The results indicated that the dynamics of the interaction were stable, and the binding was strong. In silico cloning and optimization analysis revealed an optimized sequence with a GC content of 49.776 % and a CAI of 0.982. The immunological simulation results showed strong immune responses, with elevated levels of active and plasma B-cells, regulatory T-cells, HTL, and CTL in both IgM+IgG and secondary immune responses. The antigen was completely cleared by the 50th day. This study lays the foundation for creating a potent and secure vaccine candidate to combat the newly identified M. pulmonis infection in people.

T-B cell epitope peptides induce protective immunity against Mycoplasma pneumoniae respiratory tract infection in BALB/c mice

Design of a novel multiepitope vaccine with CTLA-4 extracellular domain against Mycoplasma pneumoniae: A vaccine-immunoinformatics approach

Expression and Immunological Characterization of the Major Epitope of P1 Adhesin Protein of Mycoplasma Pneumoniae and Its Clinical Application Research

An attenuated multiple genetic mutant of Mycoplasma pneumoniae imparts good immuno-protection against M. pneumoniae pneumonia in BALB/c mice

Mucosal and systemic immune responses induced by intranasal immunization of recombinant Bacillus subtilis expressing P97R1, P46 antigens of Mycoplasma hyopneumoniae .

Designing, Expression and Immunological Characterization of a Chimeric Protein of Mycoplasma Pneumoniae.

Immunization With A Zmpb-Based Protein Vaccine Could Protect Against Pneumococcal Diseases In Mice

Recombinant Tandem Epitope Vaccination Provides Cross Protection Against Actinobacillus Pleuropneumoniae Challenge in Mice

Peptides-Based Vaccine MP3RT Induced Protective Immunity Against Mycobacterium Tuberculosis Infection in a Humanized Mouse Model

The Immunogenicity of OMP31 Peptides and Its Protection Against Brucella melitensis Infection in Mice

Protective Efficacy and Immunologic Mechanism of the Recombinant Subunit Vaccine Against Actinobacillus Pleuropneumoniae in Mice

Protection Elicited by Nasal Immunization with Pneumococcal Surface Protein A (pspa) Adjuvanted with Bacterium-Like Particles Against Streptococcus Pneumoniae Infection in Mice

Immunogenicity and Protective Efficacy of a Multi-Epitope Recombinant Toxin Antigen of Pasteurella Multocida Against Virulent Challenge in Mice.

Integrated structural proteomics and machine learning-guided mapping of a highly protective precision vaccine against mycoplasma pulmonis

A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice

Immunogenicity and Protective Efficacy of Ag85A and Truncation of PstS1 Fusion Protein Vaccines Against Tuberculosis

A candidate multi-epitope vaccine against porcine reproductive and respiratory syndrome virus and Mycoplasma hyopneumoniae induces robust humoral and cellular response in mice

Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development

Protective Efficacy of a Genetic Subunit Bacterin against Actinobacillus pleuropneumoniae in Mice

Two Bordetella Bronchiseptica Attenuated Vaccine Candidates Confer Protection Against Lethal Challenge with B. Bronchiseptica and Pasteurella Multocida Toxin in Mouse Models.

An immunoinformatics-based designed multi-epitope candidate vaccine (mpme-VAC/STV-1) against Mycoplasma pneumoniae